Agomab is developing small molecule inhibitors targeting ALK5 (TGFβ1R) to treat fibrotic diseases, including fibrostenosing Crohn’s disease and idiopathic pulmonary fibrosis. Their therapies aim to maintain and restore organ function by modulating growth factor biology in affected tissues.
Funding
$332.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Fibrotic diseases, such as fibrostenosing Crohn’s disease and idiopathic pulmonary fibrosis, lead to the progressive scarring and dysfunction of affected organs. Current treatment options often fail to adequately address the underlying mechanisms driving fibrosis, resulting in limited efficacy and the potential for disease progression.
Solution
Agomab Therapeutics is developing a pipeline of small molecule inhibitors and agonistic antibodies designed to modulate growth factor biology and restore organ function in patients with fibrotic diseases. Their lead candidates, including AGMB-129 (a gut-restricted ALK5 inhibitor for fibrostenosing Crohn’s disease) and AGMB-447 (a lung-restricted ALK5 inhibitor for idiopathic pulmonary fibrosis), target key pathways involved in the fibrotic process. By selectively inhibiting ALK5, a TGFβ1 receptor, in specific tissues, Agomab's therapies aim to prevent and reverse fibrosis, ultimately improving patient outcomes. Additionally, they are developing AGMB-101, a full MET agonistic antibody for liver cirrhosis.
Target Audience
The primary target audience includes patients suffering from fibrotic diseases such as fibrostenosing Crohn’s disease, idiopathic pulmonary fibrosis and liver cirrhosis, as well as the physicians who treat them.
Features
- AGMB-129: Oral, gut-restricted small molecule ALK5 (TGFβ1R) inhibitor in Phase 2a clinical trials for fibrostenosing Crohn’s disease.
- AGMB-447: Inhaled, lung-restricted small molecule ALK5 inhibitor currently in Phase 1 clinical trials for idiopathic pulmonary fibrosis.
- AGMB-101: Full MET agonistic antibody in late-stage IND-enabling studies for the treatment of liver cirrhosis.
- Therapies designed to selectively modulate growth factor signaling in target tissues.